MDM2 — master regulator of the p53 tumor suppressor protein

THE UBIQUITIN SYSTEM

Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840 · see citing works

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · see citing works

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693 · see citing works

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651 · see citing works

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Tumor suppressor p53 is a direct transcriptional activator of the human bax gene

Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · see citing works

Participation of p53 protein in the cellular response to DNA damage.

Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · see citing works

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · see citing works

p53 is required for radiation-induced apoptosis in mouse thymocytes

Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · see citing works

Thymocyte apoptosis induced by p53-dependent and independent pathways

Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · see citing works

p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities

Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,086 · see citing works

Definition of a consensus binding site for p53

El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985 · see citing works

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · see citing works

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · see citing works

The p53-mdm-2 autoregulatory feedback loop.

Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801 · see citing works

Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage

Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797 · see citing works

Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers

Kaghad, M., Bonnet, H., Yang, A., Créancier, L., Biscan, J.-C., Valent, A., Minty, A. J., Chalon, P., Lélias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,630 · see citing works

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626 · see citing works

Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19

Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566 · see citing works

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53

Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · see citing works

Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53

Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · see citing works

The complexity of p53 modulation: emerging patterns from divergent signalsPreprint

Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,303 · see citing works

mdm2 expression is induced by wild type p53 activity.

Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · see citing works

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization

Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245 · see citing works

DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.

Di Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215 · see citing works

The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2

Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K. M., Hara, E., Vousden, K. H., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,165 · see citing works

The MDM2 gene amplification database

Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982 · see citing works

p73 is a human p53-related protein that can induce apoptosis

Jost, C. A., Marin, M. C., & Jr, W. G. K. (1997) · Nature · doi:10.1038/38298 · Cited by 948 · see citing works

Nucleolar Arf sequesters Mdm2 and activates p53

Weber, J. D., Taylor, L. J., Roussel, M. F., Sherr, C. J., & Bar-Sagi, D. (1999) · Nature Cell Biology · doi:10.1038/8991 · Cited by 940 · see citing works

Regulation of the specific DNA binding function of p53

Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1992) · Cell · doi:10.1016/0092-8674(92)90562-q · Cited by 910 · see citing works

UV Irradiation Stimulates Levels of p53 Cellular Tumor Antigen in Nontransformed Mouse Cells

Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893 · see citing works

p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes

Caelles, C., Helmberg, A., & Karin, M. (1994) · Nature · doi:10.1038/370220a0 · Cited by 843 · see citing works

p53 and E2F-1 cooperate to mediate apoptosis.

Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 836 · see citing works

DNA damage induces phosphorylation of the amino terminus of p53

Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., & Kastan, M. B. (1997) · Genes & Development · doi:10.1101/gad.11.24.3471 · Cited by 818 · see citing works

Presence of a Potent Transcription Activating Sequence in the p53 Protein

Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790 · see citing works

Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes?

Lü, X. (1993) · Cell · doi:10.1016/0092-8674(93)90496-d · Cited by 772 · see citing works

A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking

Stommel, J. M., Marchenko, N. D., Jimenez, G. S., Moll, U. M., Hope, T. J., & Wahl, G. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.6.1660 · Cited by 738 · see citing works

Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53

Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724 · see citing works

Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

Fakharzadeh, S. S., Trusko, S. P., & George, D. L. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb07676.x · Cited by 704 · see citing works

Binding and modulation of p53 by p300/CBP coactivators

Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J. A., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693 · see citing works

Mapping of the p53 and mdm-2 Interaction Domains

Chen, J., Maréchal, V., & Levine, A. J. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.7.4107 · Cited by 689 · see citing works

Recruitment of p300/CBP in p53-Dependent Signal Pathways

Avantaggiati, M. L., Ogryzko, V. V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 668 · see citing works

A new class of yeast transcriptional activators.

Ma, J., & Ptashne, M. (1987) · Cell · doi:10.1016/0092-8674(87)90015-8 · Cited by 660 · see citing works

In vivo ubiquitination and proteasome-mediated degradation of p53(1).

Maki, C. G., Huibregtse, J. M., & Howley, P. M. (1996) · PubMed · Cited by 645 · see citing works

Signaling to p53

Prives, C. (1998) · Cell · doi:10.1016/s0092-8674(00)81774-2 · Cited by 623 · see citing works

Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-Oncogene

Raycroft, L., Wu, H., & Lozano, G. (1990) · Science · doi:10.1126/science.2144364 · Cited by 620 · see citing works

Nucleo‐cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein

Roth, J., Dobbelstein, M., Freedman, D. A., Shenk, T., & Levine, A. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.2.554 · Cited by 610 · see citing works

Structural aspects of the p53 protein in relation to gene evolution.

Soussi, T., de Fromentel, C. C., & May, P. (1990) · PubMed · Cited by 608 · see citing works

E1A signaling to p53 involves the p19ARFtumor suppressorPreprint

de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C. L., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 607 · see citing works

Synergistic activation of transcription by CBP and p53

Gu, W., Shi, X.-L., & Roeder, R. G. (1997) · Nature · doi:10.1038/42972 · Cited by 596 · see citing works

Interaction between the retinoblastoma protein and the oncoprotein MDM2

Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586 · see citing works

Functions of the MDM2 oncoprotein

Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050273 · Cited by 573 · see citing works

Crystal Structure of the Tetramerization Domain of the p53 Tumor Suppressor at 1.7 Angstroms

Jeffrey, P. D., Gorina, S. S., & Pavletich, N. P. (1995) · Science · doi:10.1126/science.7878469 · Cited by 548 · see citing works

P19 ARF stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2

Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6937 · Cited by 539 · see citing works

Cloning and functional analysis of human p51, which structurally and functionally resembles p53

Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., et al. (1998) · Nature Medicine · doi:10.1038/nm0798-839 · Cited by 529 · see citing works

Nuclear Export Is Required for Degradation of Endogenous p53 by MDM2 and Human Papillomavirus E6

Freedman, D. A., & Levine, A. J. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7288 · Cited by 513 · see citing works

Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage

Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., & Shkedy, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14973 · Cited by 461 · see citing works

Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein

Martin, K., Trouche, D., Hagemeier, C., Sørensen, T. S., Thangue, N. B. L., & Kouzarides, T. (1995) · Nature · doi:10.1038/375691a0 · Cited by 454 · see citing works

p300/MDM2 complexes participate in MDM2-mediated p53 degradation

Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414 · see citing works

p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches

Lee, S., Elenbaas, B., Levine, A. J., & Griffith, J. D. (1995) · Cell · doi:10.1016/s0092-8674(05)80006-6 · Cited by 405 · see citing works

Identification of a growth suppression domain within the retinoblastoma gene product.Preprint

Qin, X. Q., Chittenden, T., Livingston, D. M., & Kaelin, W. G. (1992) · Genes & Development · doi:10.1101/gad.6.6.953 · Cited by 404 · see citing works

Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2

Unger, T., Juven‐Gershon, T., Moallem, E., Berger, M., Sionov, R. V., Lozano, G., Oren, M., & Haupt, Y. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1805 · Cited by 365 · see citing works

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363 · see citing works

Expression of Wild-type p53 Is Required for Efficient Global Genomic Nucleotide Excision Repair in UV-irradiated Human Fibroblasts

Ford, J. M., & Hanawalt, P. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.44.28073 · Cited by 358 · see citing works

Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line

CAHILLY, L. A., Yang‐Feng, T. L., Francke, U., & George, D. L. (1987) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01535205 · Cited by 355 · see citing works

Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53

Tao, W., & Levine, A. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3077 · Cited by 355 · see citing works

Mutations in Human ARF Exon 2 Disrupt Its Nucleolar Localization and Impair Its Ability to Block Nuclear Export of MDM2 and p53

Zhang, Y., & Xiong, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80351-2 · Cited by 347 · see citing works

Big Brother

Davies, S. (1997) · Cited by 342 · see citing works

MDM2 suppresses p73 function without promoting p73 degradation

Zeng, X., Chen, L., Jost, C. A., Maya, R., Keller, D., Wang, X., Kaelin, W. G., Oren, M., Chen, J., & Lu, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3257 · Cited by 334 · see citing works

Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.

Barak, Y., Gottlieb, E., Juven-Gershon, T., & Oren, M. (1994) · Genes & Development · doi:10.1101/gad.8.15.1739 · Cited by 328 · see citing works

MDM2 interacts with MDMX through their RING finger domains

Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324 · see citing works

p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding

MIDGLEY, C. A., & Lane, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201459 · Cited by 313 · see citing works

High-Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR

Clore, G. M., Omichinski, J. G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E., & Gronenborn, A. M. (1994) · Science · doi:10.1126/science.8023159 · Cited by 306 · see citing works

DNA damage‐inducible phosphorylation of p53 at N‐terminal sites including a novel site, Ser20, requires tetramerization

Shieh, S.-Y., Taya, Y., & Prives, C. (1999) · The EMBO Journal · doi:10.1093/emboj/18.7.1815 · Cited by 299 · see citing works

The INK4a/ARF tumor suppressor: one gene—two products—two pathways

Chin, L., Pomerantz, J. H., & DePinho, R. A. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01236-5 · Cited by 286 · see citing works

Transgenic mice with p53‐responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo

Komarova, E. A., Chernov, M. V., Franks, R., Wang, K., Armin, G., Zelnick, C. R., Chin, D. M., Bacus, S. S., Stark, G. R., & Gudkov, A. V. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1391 · Cited by 272 · see citing works

Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway.

Chen, C. Y., Oliner, J., Zhan, Q., Fornace, A. J., Vogelstein, B., & Kastan, M. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.7.2684 · Cited by 271 · see citing works

Mdm2: keeping p53 under control

Piette, J. G., Neel, H., & Maréchal, V. (1997) · Oncogene · doi:10.1038/sj.onc.1201432 · Cited by 268 · see citing works

Solution structure of the tetrameric minimum transforming domain of p53

Lee, W., Harvey, T. S., Yin, Y., Yau, P., Litchfield, D. W., & Arrowsmith, C. H. (1994) · Nature Structural & Molecular Biology · doi:10.1038/nsb1294-877 · Cited by 265 · see citing works

The p53 protein is an unusually shaped tetramer that binds directly to DNA.

Friedman, P. N., Chen, X., Bargonetti, J., & Prives, C. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3319 · Cited by 264 · see citing works

RB Regulates the Stability and the Apoptotic Function of p53 via MDM2

Hsieh, J.-K., Chan, F., O’Connor, D. J., Mittnacht, S., Zhong, S., & Lü, X. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80309-3 · Cited by 255 · see citing works

p53 Protein Exhibits 3′-to-5′ Exonuclease Activity

Mummenbrauer, T., Janus, F., Müller, B., Wiesmüller, L., Deppert, W., & Große, F. (1996) · Cell · doi:10.1016/s0092-8674(00)81309-4 · Cited by 249 · see citing works

Untitled work

(1997) · PubMed · Cited by 243 · see citing works

Immunochemical analysis of the interaction of p53 with MDM2;--fine mapping of the MDM2 binding site on p53 using synthetic peptides.

Picksley, S. M., Vojtĕsek, B., Sparks, A., & Lane, D. P. (1994) · PubMed · Cited by 238 · see citing works

Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.

Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., & Finlay, C. A. (1997) · Genes & Development · doi:10.1101/gad.11.6.714 · Cited by 235 · see citing works

Transcription Factor E2F-1 Is Upregulated in Response to DNA Damage in a Manner Analogous to That of p53

Blattner, C., Sparks, A., & Lane, D. P. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3704 · Cited by 213 · see citing works

Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look

Soussi, T., & May, P. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0425 · Cited by 203 · see citing works

Regulation of Mdm2-Directed Degradation by the C Terminus of p53

Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M. A., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5690 · Cited by 193 · see citing works

Mdm2: The Ups and Downs

Juven‐Gershon, T., & Oren, M. (1999) · Molecular Medicine · doi:10.1007/bf03402141 · Cited by 193 · see citing works

Mutations in serines 15 and 20 of human p53 impair its apoptotic activity

Unger, T., Sionov, R. V., Moallem, E., Yee, C., Howley, P. M., Oren, M., & Haupt, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1202656 · Cited by 190 · see citing works

Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes.

Olson, D. C., Maréchal, V., Momand, J. A., Chen, J., Romocki, C., & Levine, A. J. (1993) · PubMed · Cited by 188 · see citing works

The cellular oncogene p53 can be activated by mutagenesis

Jenkins, J. R., Rudge, K., Chumakov, P. M., & Currie, G. A. (1985) · Nature · doi:10.1038/317816a0 · Cited by 166 · see citing works

The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain

Elenbaas, B., Dobbelstein, M., Roth, J. C., Shenk, T. E., & Levine, A. J. (1996) · Molecular Medicine · doi:10.1007/bf03401903 · Cited by 164 · see citing works

Transgenic mouse model for studying the transcriptional activity of the p53 protein: age‐ and tissue‐dependent changes in radiation‐induced activation during embryogenesis

Gottlieb, E., Haffner, R., King, A., Asher, G., Gruss, P., Lonai, P., & Oren, M. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1381 · Cited by 164 · see citing works

Inactivation of the p53-homologue p73 by the mdm2-oncoprotein

Dobbelstein, M., Wienzek, S., König, C., & Roth, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202512 · Cited by 161 · see citing works

Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage

Chen, L., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.195 · Cited by 159 · see citing works

Interaction of p53 with Its Consensus DNA-Binding Site

Wang, Y., Schwedes, J. F., Parks, D., Mann, K., & Tegtmeyer, P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2157 · Cited by 149 · see citing works

An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs.

Laín, S., Midgley, C., Sparks, A., Lane, E., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4433 · Cited by 144 · see citing works

Translational regulation of human p53 gene expression.

Fu, L., Minden, M. D., & Benchimol, S. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00812.x · Cited by 138 · see citing works

DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage

Jimenez, G. S., Bryntesson, F., Torres‐Arzayus, M. I., Priestley, A., Beeche, M., Saito, S., Sakaguchi, K., Appella, E., Jeggo, P. A., Taccioli, G. E., et al. (1999) · Nature · doi:10.1038/21913 · Cited by 130 · see citing works

MDM2-arbiter of p53's destruction

Lane, D. P., & Hall, P. A. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01119-5 · Cited by 126 · see citing works

Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2

Maki, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16531 · Cited by 125 · see citing works

Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis

Chen, L., Marechal, V., Moreau, J., Levine, A. J., & Chen, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22966 · Cited by 121 · see citing works

Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53‐mediated growth arrest.

Barak, Y., & Oren, M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05270.x · Cited by 119 · see citing works

p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53

Wasylyk, C., Salvi, R., Argentini, M., Dureuil, C., Delumeau, I., Abecassis, J., Debüssche, L., & Wasylyk, B. (1999) · Oncogene · doi:10.1038/sj.onc.1202528 · Cited by 112 · see citing works

Analysis of the degradation function of Mdm2.

Kubbutat, M. H. G., Ludwig, R., Levine, A. J., & Vousden, K. H. (1999) · PubMed · Cited by 102 · see citing works

Identification of the MDM2 Oncoprotein as a Substrate for CPP32-like Apoptotic Proteases

Erhardt, P., Tomaselli, K. J., & Cooper, G. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15049 · Cited by 100 · see citing works

MDM2 Protein Overexpression Promotes Proliferation and Survival of Multiple Myeloma Cells

Teoh, G. K. H., Urashima, M., Ogata, A., Chauhan, D., DeCaprio, J. A., Treon, S. P., Schlossman, R. L., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v90.5.1982 · Cited by 97 · see citing works

Deletion of 5'-coding sequences of the cellular p53 gene in mouse erythroleukemia: a novel mechanism of oncogene regulation.

Rovinski, B., Munroe, D. G., Peacock, J. W., Mowat, M. R. A., Bernstein, A., & Benchimol, S. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.2.847 · Cited by 96 · see citing works

Murine Double Minute (MDM2) Blocks p53-coactivator Interaction, a New Mechanism for Inhibition of p53-dependent Gene Expression

Wadgaonkar, R., & Collins, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.20.13760 · Cited by 93 · see citing works

The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger

Boddy, M. N., Freemont, P. S., & Borden, K. L. B. (1994) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(94)90020-5 · Cited by 91 · see citing works

The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2

Jones, S. N., Sands, A., Hancock, A. R., Vogel, H. S., Donehower, L. A., Linke, S. P., Wahl, G. M., & Bradley, A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14106 · Cited by 87 · see citing works

Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2

Blaydes, J. P., Gire, V., Rowson, J., & Wynford‐Thomas, D. (1997) · Oncogene · doi:10.1038/sj.onc.1201018 · Cited by 67 · see citing works

The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2

Blaydes, J. P., & Wynford‐Thomas, D. (1998) · Oncogene · doi:10.1038/sj.onc.1201880 · Cited by 63 · see citing works

The mdm2 Proto-Oncogene

Haines, D. S. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709051772 · Cited by 57 · see citing works

Up-regulated P21CIP1 expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis

Duttaroy, A., Qian, J.-F., Smith, J. S., & Wang, E. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970301)64:3 · Cited by 51 · see citing works

Metal and RNA Binding Properties of the hdm2 RING Finger Domain

Lai, Z., Freedman, D. A., Levine, A. J., & McLendon, G. L. (1998) · Biochemistry · doi:10.1021/bi980596r · Cited by 49 · see citing works

Differential cell cycle checkpoint response in normal human keratinocytes and fibroblasts.

Flatt, P. M., Price, J. O., Shaw, A. T., & Pietenpol, J. A. (1998) · PubMed · Cited by 48 · see citing works

p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms.

Haupt, Y., Rowan, S., Shaulian, E., Kazaz, A., Vousden, K. H., & Oren, M. (1997) · PubMed · Cited by 48 · see citing works

Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.

Marston, N., Jenkins, J. R., & Vousden, K. H. (1995) · PubMed · Cited by 47 · see citing works

mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts.

McMasters, K. M., Luna, R. M. D. O., Peña, J., & Lozano, G. (1996) · PubMed · Cited by 47 · see citing works

Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis

Maréchal, V., Elenbaas, B., Taneyhill, L. A., Piette, J., Méchali, M., Nicolas, J., Levine, A. J., & Moreau, J. (1997) · Oncogene · doi:10.1038/sj.onc.1200967 · Cited by 41 · see citing works

Solution conformation of an essential region of the p53 transactivation domain

Botuyan, M. V., Momand, J. A., & Chen, Y. (1997) · Folding and Design · doi:10.1016/s1359-0278(97)00047-3 · Cited by 37 · see citing works

p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts

Kurokawa, K., Tanaka, T., & Kato, J. (1999) · Oncogene · doi:10.1038/sj.onc.1202628 · Cited by 37 · see citing works

p53 and mdm2 are expressed independently during cellular proliferation.

Mosner, J., & Deppert, W. (1994) · PubMed · Cited by 29 · see citing works

Overproduction of MDM2 in vivo disrupts S phase independent of E2F1.

Reinke, V., Bortner, D. M., Amelse, L. L., Lundgren, K., Rosenberg, M. P., Finlay, C. A., & Lozano, G. (1999) · PubMed · Cited by 25 · see citing works

On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2

Blommers, M. J. J., Fendrich, G., Garcı́a-Echeverrı́a, C., & Chêne, P. (1997) · Journal of the American Chemical Society · doi:10.1021/ja9633171 · Cited by 24 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Gamma knife radiosurgery for trigeminal neuralgia associated with multiple sclerosis

Rogers, L., Shetter, A. G., Ponce, F. A., Fiedler, J. A., Smith, K. A., & Speiser, B. L. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.97.supplement_5.0529 · Cited by 1,688 · see citing works

Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies

Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D’Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,670 · see citing works

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.

Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571 · see citing works

The proteasome: a suitable antineoplastic target

Adams, J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1361 · Cited by 1,200 · see citing works

Promoting apoptosis as a strategy for cancer drug discovery

Fesik, S. W. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1736 · Cited by 1,095 · see citing works

Decision making by p53: life, death and cancer

Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,063 · see citing works

Dynamics of the p53-Mdm2 feedback loop in individual cells

Lahav, G., Rosenfeld, N., Sigal, A., Geva‐Zatorsky, N., Levine, A. J., Elowitz, M. B., & Alon, U. (2004) · Nature Genetics · doi:10.1038/ng1293 · Cited by 1,015 · see citing works

HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation

Zhou, B. P., Liao, Y., Xia, W., Zou, Y., Spohn, B., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-973 · Cited by 951 · see citing works

Regulation of p53 activity through lysine methylation

Chuikov, S., Kurash, J. K., Wilson, J. R., Xiao, B., Justin, N., Ivanov, G. S., McKinney, K. M., Tempst, P., Prives, C. L., Gamblin, S. J., et al. (2004) · Nature · doi:10.1038/nature03117 · Cited by 820 · see citing works

The p53–Mdm2 module and the ubiquitin system

Michael, D., & Oren, M. (2002) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 759 · see citing works

ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage

Maya, R., Balass, M., Kim, S.-T., Shkedy, D., Leal, J.-F. M., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., et al. (2001) · Genes & Development · doi:10.1101/gad.886901 · Cited by 716 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 657 · see citing works

Oscillations and variability in the p53 system

Geva‐Zatorsky, N., Rosenfeld, N., Itzkovitz, S., Milo, R., Sigal, A., Dekel, E., Yarnitzky, T., Liron, Y., Polak, P. P., Lahav, G., et al. (2006) · Molecular Systems Biology · doi:10.1038/msb4100068 · Cited by 640 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

The molecular biology of cancer

Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 592 · see citing works

Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53

Katayama, H. G., Sasai, K., Kawai, H., Yuan, Z.-M., Bondaruk, J. E., Suzuki, F., Fujii, S., Arlinghaus, R. B., Czerniak, B. A., & Sen, S. (2003) · Nature Genetics · doi:10.1038/ng1279 · Cited by 586 · see citing works

The role of p53 in cancer drug resistance and targeted chemotherapy

Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2016) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 590 · see citing works

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

Gottlieb, T. M., Martínez-Leal, J. F., Seger, R., Taya, Y., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205181 · Cited by 473 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

Genetic Susceptibility to Cancer

Dong, L. M., Potter, J. D., White, E., Ulrich, C. M., Cardon, L. R., & Peters, U. (2008) · JAMA · doi:10.1001/jama.299.20.2423 · Cited by 459 · see citing works

Regulating tumor suppressor genes: post-translational modifications

Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449 · see citing works

E3 ubiquitin ligases: styles, structures and functions

Yang, Q., Zhao, J., Chen, D., & Wang, Y. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00043-2 · Cited by 435 · see citing works

Structure–function–rescue: the diverse nature of common p53 cancer mutants

Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 430 · see citing works

p53-Dependent apoptosis pathways

Shen, Y., & White, E. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)82002-9 · Cited by 415 · see citing works

The PTEN, Mdm2, p53 tumor suppressor–oncoprotein network

Mayo, L. D., & Donner, D. B. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02166-7 · Cited by 408 · see citing works

Targeting cell cycle regulation in cancer therapy

Díaz‐Moralli, S., Tarrado‐Castellarnau, M., Miranda, A., & Cascante, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.011 · Cited by 361 · see citing works

SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression

Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328 · see citing works

Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment

Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S., Liu, J., Wei, T., Cao, W., Zou, G., & Liang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.058 · Cited by 315 · see citing works

Amplification of <i>Mdmx</i> (or <i>Mdm4</i> ) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity

Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310 · see citing works

MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310 · see citing works

p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products

Yin, Y., Stephen, C. W., Luciani, M. G., & Fåhræus, R. (2002) · Nature Cell Biology · doi:10.1038/ncb801 · Cited by 305 · see citing works

p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis

Wang, X., Simpson, E. R., & Brown, K. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0563 · Cited by 304 · see citing works

Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges

Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300 · see citing works

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

Sur, S., Pagliarini, R. A., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 293 · see citing works

Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation

Feng, J., Tamaskovic, R., Yang, Z., Brazil, D. P., Merlo, A., Hess, D., & Hemmings, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404936200 · Cited by 294 · see citing works

Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function

Korgaonkar, C. K., Hagen, J., Tompkins, V. S., Frazier, A. A., Allamargot, C., Quelle, F. W., & Quelle, D. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1258-1271.2005 · Cited by 290 · see citing works

The p53 and Mdm2 families in cancer

Michael, D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00264-7 · Cited by 288 · see citing works

Posttranslational modification of MDM2.

Meek, D. W., & Knippschild, U. (2003) · PubMed · Cited by 280 · see citing works

Control of the G2/M Transition

Stark, G. R., & Taylor, W. R. (2006) · Molecular Biotechnology · doi:10.1385/mb:32:3:227 · Cited by 279 · see citing works

The roles of nucleolin subcellular localization in cancer

Berger, C., Gaume, X., & Bouvet, P. (2015) · Biochimie · doi:10.1016/j.biochi.2015.03.023 · Cited by 269 · see citing works

p63 and p73 in human cancer: defining the network

DeYoung, M. P., & Ellisen, L. W. (2007) · Oncogene · doi:10.1038/sj.onc.1210337 · Cited by 261 · see citing works

T Antigens of Simian Virus 40: Molecular Chaperones for Viral Replication and Tumorigenesis

Sullivan, C. S., & Pipas, J. M. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.2.179-202.2002 · Cited by 259 · see citing works

Well-differentiated and dedifferentiated liposarcomas

Coindre, J., Pédeutour, F., & Aurias, A. (2009) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-009-0815-x · Cited by 254 · see citing works

Structural conservation of druggable hot spots in protein–protein interfaces

Kozakov, D., Hall, D. R., Chuang, G., Cencic, R., Brenke, R., Grove, L. E., Beglov, D., Pelletier, J., Whitty, A., & Vajda, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101835108 · Cited by 245 · see citing works

Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics

Πέττα, Ι., Lievens, S., Libert, C., Tavernier, J. H., & Bosscher, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240 · see citing works

The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma

Slack, A., Chen, Z., Tonelli, R., Pulè, M. A., Hunt, L., Pession, A., & Shohet, J. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405495102 · Cited by 235 · see citing works

Ubiquitination and Degradation of Mutant p53

Lukashchuk, N., & Vousden, K. H. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-07 · Cited by 223 · see citing works

Discovery of 4-((3′ <i>R</i> ,4′ <i>S</i> ,5′ <i>R</i> )-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Aguilar, A., Lu, J., Liu, L., Du, D., Bernard, D., McEachern, D., Przybranowski, S., Li, X., Luo, R., Wen, B., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01665 · Cited by 211 · see citing works

Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase

Inuzuka, H., Tseng, A., Gao, D., Zhai, B., Zhang, Q. H., Shaik, S., Wan, L., Cambronne, X. A., Mock, C. S., Yin, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.015 · Cited by 205 · see citing works

Targeting the p53–MDM2 interaction to treat cancer

Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204 · see citing works

Tyrosine phosphorylation of Mdm2 by c‐Abl: implications for p53 regulation

Goldberg, Z., Sionov, R. V., Berger, M., Zwang, Y., Perets, R., Etten, R. A. V., Oren, M., Taya, Y., & Haupt, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf384 · Cited by 200 · see citing works

Alternative and aberrant splicing of MDM2 mRNA in human cancer

Bartel, F., Taubert, H. W., & Harris, L. C. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00091-0 · Cited by 196 · see citing works

Analyzing the G2/M Checkpoint

Stark, G. R., & Taylor, W. R. (2004) · Humana Press eBooks · doi:10.1385/1-59259-788-2:051 · Cited by 195 · see citing works

MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins

Kobet, E., Zeng, X., Zhu, Y., Keller, D., & Lu, H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12547 · Cited by 193 · see citing works

mdmx is a negative regulator of p53 activity in vivo.

Finch, R. A., Donoviel, D. B., Potter, D., Shi, M., Fan, A., Freed, D. D., Wang, C.-Y., Zambrowicz, B., Ramírez‐Solis, R., Sands, A., et al. (2002) · PubMed · Cited by 192 · see citing works

Molecular mechanisms of cerebral ischemia-induced neuronal death

Hou, S., & MacManus, J. P. (2002) · International review of cytology · doi:10.1016/s0074-7696(02)21011-6 · Cited by 184 · see citing works

Bax Loss Impairs Myc-Induced Apoptosis and Circumvents the Selection of p53 Mutations during Myc-Mediated Lymphomagenesis

Eischen, C. M., Roussel, M. F., Korsmeyer, S. J., & Cleveland, J. L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.22.7653-7662.2001 · Cited by 183 · see citing works

β-Peptides as inhibitors of protein–protein interactions

Kritzer, J. A., Stephens, O. M., Guarracino, D. A., Reznik, S. K., & Schepartz, A. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.09.009 · Cited by 182 · see citing works

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

Stühmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R. A., Daniel, P. T., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1489 · Cited by 180 · see citing works

Implications of Oxidative Stress and Cell Membrane Lipid Peroxidation in Human Cancer (Spain)

Cejas, P., Casado, E., Belda-Iniesta, C., de Castro, J., Espinosa, E., Redondo, A., Sereno, M., García‐Cabezas, M. Á., Vara, J. Á. F., Domínguez-Cáceres, A., et al. (2004) · Cancer Causes & Control · doi:10.1023/b:caco.0000036189.61607.52 · Cited by 177 · see citing works

Stress-Dependent Nucleolin Mobilization Mediated by p53-Nucleolin Complex Formation

Daniely, Y., Dimitrova, D. D., & Borowiec, J. A. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.6014-6022.2002 · Cited by 170 · see citing works

ATM-Mediated Phosphorylations Inhibit Mdmx/Mdm2 Stabilization by HAUSP in Favor of p53 Activation

Meulmeester, E., Pereg, Y., Shiloh, Y., & Jochemsen, A. G. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1981 · Cited by 166 · see citing works

Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment

Gupta, A., Shah, K., Oza, M. J., & Behl, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.155 · Cited by 166 · see citing works

The ubiquitin–proteasome system in cardiovascular diseases—a hypothesis extended

Herrmann, S. M. (2003) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.09.033 · Cited by 163 · see citing works

Molecular knots in biology and chemistry

Lim, N. C. H., & Jackson, S. (2015) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/27/35/354101 · Cited by 161 · see citing works

Sp1 Plays a Critical Role in the Transcriptional Activation of the Human Cyclin-dependent Kinase Inhibitor p21 Gene by the p53 Tumor Suppressor Protein

Koutsodontis, G., Tentes, I. K., Papakosta, P., Moustakas, A., & Kardassis, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104130200 · Cited by 159 · see citing works

Regulating the Regulators: Control of Protein Ubiquitination and Ubiquitin-like Modifications by Extracellular Stimuli

Gao, M., & Karin, M. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.017 · Cited by 159 · see citing works

Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma

Maerken, T. V., Speleman, F., Vermeulen, J., Lambertz, I., Clercq, S. D., Smet, E. D., Yigit, N., Coppens, V., Philippé, J., Paepe, A. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0792 · Cited by 154 · see citing works

Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation.

Yang, H. S., Filipovic, Z., Brown, D. A., Breit, S. N., & Vassilev, L. T. (2003) · PubMed · Cited by 157 · see citing works

Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development

Xiong, S., Van Pelt, C. S., Elizondo-Fraire, A. C., Liu, G., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508500103 · Cited by 155 · see citing works

Does p53 affect organismal aging?

Donehower, L. A. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10104 · Cited by 155 · see citing works

Probing the Structural Requirements of Peptoids That Inhibit HDM2−p53 Interactions

Hara, T. J., Durell, S. R., Myers, M. C., & Appella, D. H. (2006) · Journal of the American Chemical Society · doi:10.1021/ja056344c · Cited by 155 · see citing works

Breaking Bad: How Viruses Subvert the Cell Cycle

Fan, Y., Sanyal, S., & Bruzzone, R. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00396 · Cited by 147 · see citing works

Phosphorylation of Human p53 at Serine 46 Determines Promoter Selection and whether Apoptosis Is Attenuated or Amplified

Mayo, L. D., Seo, Y. R., Jackson, M. W., Smith, M. L., Guzman, J. R., Korgaonkar, C. K., & Donner, D. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503026200 · Cited by 146 · see citing works

Untitled work

(2003) · PubMed · Cited by 147 · see citing works

DNA Double-Strand Breaks

Bross, L., Muramatsu, M., Kinoshita, K., Honjo, T., & Jacobs, H. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011749 · Cited by 145 · see citing works

Hypophosphorylation of Mdm2 Augments p53 Stability

Blattner, C., Hay, T., Meek, D. W., & Lane, D. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.17.6170-6182.2002 · Cited by 144 · see citing works

Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2

de Graaf, P., Little, N. A., Ramos, Y. F. M., Meulmeester, E., Letteboer, S. J. F., & Jochemsen, A. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213034200 · Cited by 143 · see citing works

Massively regulated genes: the example of TP53

Hollstein, M. C., & Hainaut, P. L. (2009) · The Journal of Pathology · doi:10.1002/path.2637 · Cited by 142 · see citing works

Structure of Free MDM2 N-terminal Domain Reveals Conformational Adjustments that Accompany p53-binding

Uhrı́nová, S., Uhrı́n, D., Powers, H., Watt, K., Zheleva, D. I., Fischer, P. M., McInnes, C., & Barlow, P. N. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.05.010 · Cited by 141 · see citing works

The p53 protein family and radiation sensitivity: Yes or no?

Cuddihy, A. R., & Bristow, R. G. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031764.81141.e4 · Cited by 136 · see citing works

Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours

Aleixo, P. B., Hartmann, A., de Menezes, I. C. B., Meurer, R. T., & Oliveira, A. M. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.070201 · Cited by 135 · see citing works

β-Arrestin 2 Functions as a G-Protein-coupled Receptor-activated Regulator of Oncoprotein Mdm2

Wang, P., Gao, H., Ni, Y., Wang, B., Wu, Y., Ji, L., Qin, L.-H., Ma, L., & Pei, G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210350200 · Cited by 134 · see citing works

Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods

Waters, M. D., Jackson, M. A., & Lea, I. A. (2010) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2010.04.005 · Cited by 133 · see citing works

Dual Role of p53 in Innate Antiviral Immunity

Rivas, C., Aaronson, S. A., & Muñoz‐Fontela, C. (2010) · Viruses · doi:10.3390/v2010298 · Cited by 131 · see citing works

Germline mutation of ARF in a melanoma kindred

Hewitt, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.11.1273 · Cited by 132 · see citing works

Functional analysis and intracellular localization of p53 modified by SUMO-1

Kwek, S. S., Derry, J. J., Tyner, A. L., Shen, Z., & Gudkov, A. V. (2001) · Oncogene · doi:10.1038/sj.onc.1204362 · Cited by 130 · see citing works

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

de Jonge, M. J. A., de Weger, V. A., Dickson, M. A., Langenberg, M. H. G., Cesne, A. L., Wagner, A. J., Hsu, K., Zheng, W., Macé, S., Tuffal, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.005 · Cited by 130 · see citing works

Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis

Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129 · see citing works

DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation

Okamoto, K., Kashima, K., Pereg, Y., Ishida, M., Yamazaki, S., Nota, A., Teunisse, A., Migliorini, D., Kitabayashi, I., Marine, J.-C., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9608-9620.2005 · Cited by 129 · see citing works

Inhibiting S100B Restores p53 Levels in Primary Malignant Melanoma Cancer Cells

Lin, J., Yang, Q., Yan, Z., Markowitz, J., Wilder, P. T., Carrier, F., & Weber, D. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405419200 · Cited by 128 · see citing works

Dysregulation of cellular signaling by HER2 in breast cancer

Zhou, B. P. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.006 · Cited by 127 · see citing works

Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways.

Zhao, L., Samuels, T. L., Winckler, S., Korgaonkar, C. K., Tompkins, V. S., Horne, M. C., & Quelle, D. E. (2003) · PubMed · Cited by 126 · see citing works

p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop

Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 126 · see citing works

Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention

Saha, A., Kaul, R., Murakami, M., & Robertson, E. S. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13923 · Cited by 123 · see citing works

Histone methylation modifiers in cellular signaling pathways

Alam, H., Gu, B., & Lee, M. G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2023-y · Cited by 119 · see citing works

Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants

Joerger, A. C., & Fersht, A. R. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 122 · see citing works

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

Tundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 115 · see citing works

254 INVITED Small molecule inhibitors of the human MDM2-p53 interaction as anticancer agents

Wang, S., Shangary, S. K., Qin, Q., McEachern, D., Ding, K., Nikolovska‐Coleska, Z., Lu, Y., Malek, S. N., Guo, M., & Yang, D. (2008) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(08)72188-8

MDM2 and MDMX Regulators of p53 Activity

Momand, J. A., Aspuria, P. J., & Furuta, S. (2007) · Springer eBooks · doi:10.1007/0-387-30127-5_7 · Cited by 1 · see citing works

The regulation of MDM2 oncogene and its impact on human cancers

YuHan, Zhao, Haiyang, Yu, Wenwei, & Hu (2014) · 生物化学与生物物理学报：英文版 · Cited by 1 · see citing works

mdm-2 Inhibits the G1 Arrest and Apoptosis Functions of the p53 Tumor Suppressor Protein

Chen, J., Wu, X., Lin, J., & Levine, A. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.5.2445 · Cited by 350 · see citing works

p76MDM2 Inhibits the Ability of p90MDM2to Destabilize p53

Perry, M. E., Mendrysa, S. M., Saucedo, L. J., Tannous, P., & Holubar, M. K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5733 · Cited by 71 · see citing works